编号：2018-11-29-1 证券代码：300391 证券简称：康跃科技 康跃科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|------------------------------|--------------------------------------------------------------| | | | | | 投资者关系活 | √ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | 财通证券股份有限公司：龚斯闻 | | | 及人员姓名 | | 国泰君安证券股份有限公司：石金漫 | | | 招商证券股份有限公司：普绍增 | | | | | 中银国际证券股份有限公司：李可伦 | | 时间 | 2108 年 11 月 | 29 日 14:00-17:00 | | 地点 | 山东寿光经济开发区洛前街 | 1 号公司会议室 | | 上市公司接待 | 总 ...

证券代码：300391 证券简称：康跃科技 编号：2019-01-22-1 康跃科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|------------------------------|--------------------------------------------------------------| | | | | | 投资者关系活 | √ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | √ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 大成基金管理有限公司：王晶晶；农银汇理基金管理有限公司：刘世 | | 及人员姓名 | | 昌；华夏基金管理有限公司：钟帅；海通证券股份有限公司：杨震； | | | | 华泰证券股份有限公司：祁滕、肖群溪；华创证券：杨达伟；千和资 | | | | 本管理有限公司：崔同魁；拾贝投资管理（北京）有限公司：秦雪峰 | | 时间 | 2019 年 1 月 22 | ...

证券代码：300391 证券简称：康跃科技 康跃科技股份有限公司投资者关系活动记录表 编号：2021-05-07-1 | --- | --- | --- | |-------------------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300391 证券简称：康跃科技 康跃科技股份有限公司投资者关系活动记录表 编号：2022-05-06-1 | --- | --- | --- | |-------------------------|----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活 | □特定对象调研 | □分析师会议 | | 动类别 | □媒体采访 √业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | （请文 ...

证券代码：300391 证券简称：康跃科技 康跃科技股份有限公司投资者关系活动记录表 编号：2022-11-16-1 | --- | --- | --- | |-------------------------|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活 | □特定对象调研 | □分析师会议 | | 动类别 | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | √其他 | （山东辖区上市公司 2022 年度投资者网上集体接待日活动） | | 参与单位名称 及人员姓名 | 参与公司 2022 | 年度投资者网上集体接待日活动的投资者 | | 时间 | ...

证券代码：300391 证券简称：康跃科技 公告编号：2022-109 康跃科技股份有限公司 关于参加山东辖区上市公司 2022 年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 为进一步加强与广大投资者的互动交流，康跃科技股份有限公司（以下简称"公 司"）将于2022年11月16日（星期三）14:00—16:00参加由山东证监局、山东上市 公司协会联合举办，深圳市全景网络有限公司承办的"山东辖区上市公司2022年度 投资者网上集体接待日活动"，现将有关事项公告如下： 本次投资者网上集体接待日活动将在深圳市全景网络有限公司提供的网上平 台采取网络远程的方式举行，投资者可以登录全景网"投资者关系互动平台" (http://ir.p5w.net/）参与本次活动。 公司总经理罗明先生、董事会秘书宁潞宏先生、财务总监胡正盈先生及副总经 理杨月晓先生将通过网络在线形式与投资者进行沟通交流，欢迎广大投资者积极参 与。 特此公告。 康跃科技股份有限公司董事会 2022年11月14日 ...

证券代码：300391 证券简称：康跃科技 康跃科技股份有限公司投资者关系活动记录表 编号：2022-09-21-1 | --- | --- | --- | |-------------------------|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活 | √特定对象调研 | □分析师会议 | | 动类别 | □媒体采访 □业绩说明会 | | ...

康跃科技股份有限公司 2022 年第三季度报告 证券代码：300391 证券简称：康跃科技 公告编号：2022-105 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 康跃科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 1 康跃科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 430,797,479.50 | -17.26% | 1,422,647,907.32 | -21.76% | | 归属于上市公司股东 | 67,700,721.70 | 432.85% | 27,425,057.22 | ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2022, representing a 20% growth compared to the same period last year[15]. - The company's operating revenue for the reporting period was ¥991,850,427.82, a decrease of 23.56% compared to ¥1,297,636,956.91 in the same period last year[23]. - The net profit attributable to shareholders was -¥40,275,664.48, representing a decline of 147.95% from ¥83,994,308.73 in the previous year[23]. - The total revenue for the reporting period was 991.85 million yuan, a decrease of 23.56% year-on-year, with a net profit attributable to shareholders of -40.28 million yuan, a decline of 147.95%[41]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2022, representing a year-over-year growth of 25%[113]. - The company reported a total operating revenue of 991.85 million yuan, a decrease of 23.56% year-on-year, and a net profit attributable to shareholders of -40.28 million yuan, a decline of 147.95% compared to the previous year[84]. User Growth - User data indicates a growth in active users, reaching 1.2 million, which is a 15% increase year-over-year[15]. - User data showed a total of 10 million active users by the end of June 2022, an increase of 15% compared to the previous year[123]. - The company has a strong marketing system and has established a solid customer base in the internal combustion engine parts market[37]. Future Outlook - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 25%[15]. - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 20% to 30% based on current market trends and user acquisition strategies[122]. - The company plans to expand its main business to include traditional Chinese medicine, hollow capsules, and pharmaceutical wholesale after a major asset restructuring[88]. - The company plans to control shipments to manage accounts receivable and reduce channel inventory in response to market conditions[85]. Product Development - New product development includes the launch of a cutting-edge technology platform aimed at enhancing user experience, expected to be fully operational by Q4 2022[15]. - New product launches are expected to contribute an additional 200 million in revenue by the end of 2022[113]. - The company has developed a series of capsule formulations to address quality demands, including anti-fracture formulations for traditional Chinese medicine capsules[44]. Market Expansion - The company is expanding its market presence by entering two new regions, which is anticipated to contribute an additional 50 million RMB in revenue[15]. - Market expansion plans include entering three new international markets by Q4 2022, aiming for a 10% market share in each[113]. - The company is actively engaged in the research and development of fuel cell electronic control turbochargers, with prototypes and performance tests recognized by clients[37]. Financial Health - The total assets of the company have increased to 1.2 billion RMB, reflecting a 10% growth from the previous year[15]. - The company's total assets reached CNY 4,279,123,989.68, up from CNY 4,214,473,787.82, reflecting an increase of about 1.5%[176]. - The company's equity attributable to shareholders decreased to CNY 786,060,645.51 from CNY 826,282,705.59, a decline of about 4.9%[176]. Research and Development - The company plans to invest 100 million RMB in research and development for new technologies over the next year[15]. - The company is investing heavily in R&D, with a budget increase of 30% for new technology development[113]. - The company has a specialized R&D team of nearly 100 people focused on core turbocharger technology innovation[52]. Risk Management - The company has identified potential risks including market competition and regulatory changes, with strategies in place to mitigate these risks[3]. - The company is closely monitoring the operating conditions of its subsidiaries to mitigate the risk of goodwill impairment following the acquisition[89]. Compliance and Governance - The company has committed to maintaining independence and compliance with relevant laws and regulations following the completion of its asset restructuring[118]. - The company has assured that it has not provided any external guarantees or allowed its funds to be used improperly by controlling entities[119]. - The company has pledged to uphold the rights and interests of its investors, committing to ethical business practices[119]. Shareholder Relations - No cash dividends or stock bonuses will be distributed to shareholders for this period, as the company focuses on reinvestment[4]. - The company has established a decision-making and operational structure involving the shareholders' meeting, board of directors, supervisory board, and management to protect shareholders' rights[102]. - The company has engaged with investors through various channels to improve understanding and communication[103].

Financial Performance - The company's operating revenue for 2021 was ¥2,361,946,450.06, representing a 94.48% increase compared to ¥1,214,503,960.24 in 2020[27]. - The net profit attributable to shareholders for 2021 was ¥49,104,524.78, a 93.94% increase from ¥25,319,988.66 in 2020[27]. - The net cash flow from operating activities reached ¥230,987,890.32, marking a significant increase of 604.11% from ¥32,805,640.00 in 2020[27]. - The basic earnings per share for 2021 was ¥0.1402, up 93.91% from ¥0.0723 in 2020[27]. - The company achieved a total revenue of CNY 2,361.95 million in 2021, representing a year-on-year growth of 94.48%[63]. - The pharmaceutical manufacturing segment generated revenue of CNY 1,558.35 million, a significant increase of 433% compared to the previous year[64]. - The company’s net profit for the reporting period was CNY 49.10 million, up 93.94% from the previous year[63]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 25%[175]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% to 1.8 billion RMB[179]. Accounts Receivable and Cash Flow - As of the end of the reporting period, accounts receivable amounted to RMB 1,377.96 million, accounting for 66.93% of current assets, indicating potential pressure on cash flow and working capital[6]. - The company aims to strengthen accounts receivable management by establishing a sales collection assessment mechanism to control the scale of accounts receivable[7]. - The company reported a significant increase in accounts receivable, which rose to ¥1,377,957,524.35, representing 32.70% of total assets, up from 25.43% in the previous year[97]. - The net increase in cash and cash equivalents was -¥24,425,776.85, an improvement of 84.13% from -¥153,893,763.91 in 2020, due to increased cash flow from operating and financing activities[92]. Strategic Goals and Commitments - The company has committed to achieving a net profit of no less than RMB 180 million for 2020 and RMB 200 million for 2021, with a cumulative target of RMB 610 million for 2020-2022, highlighting performance expectations amid market uncertainties[9]. - The company is focusing on expanding its cooperation with hospitals and increasing the variety of products sold in the pharmaceutical distribution sector[112]. - The company plans to enhance its management capabilities and integrate new pharmaceutical-related businesses, including traditional Chinese medicine and pharmaceutical wholesale, following a significant asset restructuring[8]. - The company is committed to enhancing operational efficiency and reducing costs through improved management practices[5]. Market Development and Innovation - The company is increasing efforts in market development and technological innovation to improve product competitiveness and profitability[5]. - The company is actively expanding its market share in the turbocharger sector by accelerating product technology upgrades and quality improvements[39]. - The company is focusing on integrating advanced production technologies and diversifying sales channels in the pharmaceutical excipients sector[107]. - The company is developing a traditional Chinese medicine formula aimed at treating viral pneumonia and influenza, with a clinical research success rate of over 95%[87]. Risks and Challenges - The company faces risks related to goodwill impairment due to the acquisition of new businesses, which may affect future operating performance if expectations are not met[11]. - The company acknowledges risks associated with macroeconomic fluctuations and industry policy changes that could impact product demand and operational stability[5]. - The company faces risks related to industry policies, accounts receivable, and potential goodwill impairment following its major asset restructuring[115]. Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for its directors and senior management[121]. - The company strictly adheres to relevant laws and regulations, enhancing corporate governance and internal control systems[120]. - The company has not faced any regulatory criticism regarding information disclosure during the reporting period[122]. - The company has implemented a registration management system for insider information, ensuring strict control over information disclosure[123]. Research and Development - The company has a professional R&D team focused on core turbocharger technologies, enhancing its competitive position in the internal combustion engine parts industry[44]. - The R&D investment in 2021 was ¥39,363,616.29, down from ¥43,155,449.34 in 2020, reflecting a trend of reduced investment in R&D[88]. - Research and development investments have increased by 30%, focusing on advanced technology in the pharmaceutical sector[179]. Environmental and Social Responsibility - The company has implemented measures to strictly control environmental pollution and comply with national environmental protection laws[159]. - The company actively fulfills corporate social responsibility, adhering to laws and regulations, and has contributed to local pandemic prevention efforts, including donating masks and medical supplies worth 260,000 RMB[162]. Employee and Management Structure - The total number of employees at the end of the reporting period was 1,581, with 1,576 from major subsidiaries and 5 from the parent company[145]. - The company has a performance assessment and incentive system for senior management remuneration[138]. - The management team includes professionals with backgrounds in finance, engineering, and pharmaceuticals[135].